Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.
Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 microg/liter versus 1,125 microg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly.
Neubauer
Werner Christian
WC
University Medical Center Freiburg, Department of Hematology & Oncology, Freiburg, Germany. werner.neubauer@uniklinik-freiburg.de
Engelhardt
Monika
M
König
Armin
A
Hieke
Stefanie
S
Jung
Manfred
M
Bertz
Hartmut
H
Kümmerer
Klaus
K
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D019337:Hematologic Neoplasms / Q000382:microbiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy; D011446:Prospective Studies; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole